<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047578</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCH_ALL_BuFluVP</org_study_id>
    <nct_id>NCT02047578</nct_id>
  </id_info>
  <brief_title>Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.</brief_title>
  <official_title>Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Childhood and Adolescent Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the outcome of hematopoietic stem cell transplantation using targeted busulfan,
      fludarabine, etoposide conditioning regimen in childhood and adolescent ALL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Busulfan is a highly toxic drug with narrow therapeutic window used for the conditioning of
      hematopoietic stem cell transplantation. High exposure is associated with systemic toxicity
      such as veno-occlusive disease (VOD) and underexposure is associated with graft failure or
      relapse. In this study the investigators plan to improve the outcome of hematopoietic stem
      cell transplantation by using optimal busulfan dose through pharmacokinetic study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year event free survival after hematopoietic stem cell transplantation.</measure>
    <time_frame>at 1 year</time_frame>
    <description>To evaluate 1-year event free survival after hematopoietic stem cell transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment rate</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
    <description>To evaluate engraftment rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Toxicities associated with hematopoietic stem cell transplantation</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
    <description>To evaluate toxicities associated with hematopoietic stem cell transplantation. Toxicities will be assessed with number of participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute GVHD</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
    <description>To evaluate acute GVHD</description>
  </other_outcome>
  <other_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
    <description>To evaluate chronic GVHD</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
    <description>To evaluate treatment related mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Relapse rate</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
    <description>To evaluate relapse rate</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Busulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age&lt;1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>First dose: busulfan (120 mg/m2 ivs once daily) (if age&lt;1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study</description>
    <arm_group_label>Busulfan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are diagnosed as ALL.

          2. Patients who need hematopoietic stem cell transplantation

          3. Age: up to 21 years

          4. Performance status: ECOG 0-2.

          5. Patients must be free of significant functional deficits in major organs, but the
             following eligibility criteria may be modified in individual cases. 1. Heart: a
             shortening fraction &gt; 30% and ejection fraction &gt; 45%. 2. Liver: total bilirubin &lt; 2 ×
             upper limit of normal; ALT &lt; 3 × upper limit of normal. 3. Kidney: creatinine &lt;2 ×
             normal or a creatinine clearance (GFR) &gt; 60 ml/min/1.73m2.

          6. Patients must lack any active viral infections or active fungal infection.

          7. Appropriate donor is available: Matched in 6/6 of A, B, DR loci.

          8. Patients (or one of parents if patients age &lt; 19) should sign informed consent.

        Exclusion Criteria:

          1. Pregnant or nursing women.

          2. Malignant or nonmalignant illness that is uncontrolled or whose control may be
             jeopardized by complications of study therapy.

          3. Psychiatric disorder that would preclude compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, MD, PhD</last_name>
    <phone>82 2 2072 3304</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Che Ry Hong, MD</last_name>
    <phone>82 2 2072 3778</phone>
    <email>cheryhong84@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Daehangno, Jongno-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, MD, PhD</last_name>
      <phone>82 2 2072 3304</phone>
      <email>kanghj@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji Won Lee, MD</last_name>
      <phone>82 2 2072 4192</phone>
      <email>agnesjw@hanmail.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

